HC Wainwright Has Positive Estimate for CAPR FY2024 Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR) – Equities researchers at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of ($1.33) for the year, up from their previous forecast of ($1.38). HC Wainwright currently has a “Buy” rating and a $77.00 target price on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q4 2024 earnings at ($0.30) EPS, FY2025 earnings at ($1.14) EPS and FY2026 earnings at ($0.11) EPS.

Several other brokerages have also recently commented on CAPR. Maxim Group raised their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 price target for the company. Oppenheimer restated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. Finally, Cantor Fitzgerald lifted their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock opened at $18.61 on Monday. Capricor Therapeutics has a one year low of $2.87 and a one year high of $23.40. The company has a market cap of $845.01 million, a P/E ratio of -17.56 and a beta of 4.00. The business has a fifty day moving average of $15.21 and a two-hundred day moving average of $8.50.

Insider Transactions at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The shares were acquired at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the purchase, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. The trade was a 65.21 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new stake in shares of Capricor Therapeutics during the first quarter worth about $40,000. Main Street Financial Solutions LLC grew its stake in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares during the period. SG Americas Securities LLC acquired a new position in Capricor Therapeutics in the 3rd quarter valued at $133,000. Bank of New York Mellon Corp boosted its holdings in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in Capricor Therapeutics in the third quarter valued at $161,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.